Liver cancer stem cells (CSCs) have been identified and shown to have self-renewal and differentiation properties; however, the biology of these hepatic CSCs remains largely unknown. Here, we analyzed transcriptome gene expression profiles of liver CSCs and non-CSCs from hepatocellular carcinoma (HCC) cells lines and found that the transcription factor (TF) ZIC2 is highly expressed in liver CSCs. ZIC2 was required for the self-renewal maintenance of liver CSCs, as ZIC2 depletion reduced sphere formation and xenograft tumor growth in mice. We determined that ZIC2 acts upstream of the TF OCT4 and that ZIC2 recruits the nuclear remodeling factor (NURF) complex to the OCT4 promoter, thereby initiating OCT4 activation. In HCC patients, expression levels of the NURF complex were consistent with clinical severity and prognosis. Moreover, ZIC2 and OCT4 levels positively correlated to the clinicopathological stages of HCC patients. Altogether, our results indicate that levels of ZIC2, OCT4, and the NURF complex can be detected and used for diagnosis and prognosis prediction of HCC patients. Moreover, these factors may be potential therapeutic targets for eradicating liver CSCs.
Liver cancer stem cells (CSCs) have been identified and shown to have self-renewal and differentiation properties; however, the biology of these hepatic CSCs remains largely unknown. Here, we analyzed transcriptome gene expression profiles of liver CSCs and non-CSCs from hepatocellular carcinoma (HCC) cells lines and found that the transcription factor (TF) ZIC2 is highly expressed in liver CSCs. ZIC2 was required for the self-renewal maintenance of liver CSCs, as ZIC2 depletion reduced sphere formation and xenograft tumor growth in mice. We determined that ZIC2 acts upstream of the TF OCT4 and that ZIC2 recruits the nuclear remodeling factor (NURF) complex to the OCT4 promoter, thereby initiating OCT4 activation. In HCC patients, expression levels of the NURF complex were consistent with clinical severity and prognosis. Moreover, ZIC2 and OCT4 levels positively correlated to the clinicopathological stages of HCC patients. Altogether, our results indicate that levels of ZIC2, OCT4, and the NURF complex can be detected and used for diagnosis and prognosis prediction of HCC patients. Moreover, these factors may be potential therapeutic targets for eradicating liver CSCs.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, ranking the third leading cause of cancer-related deaths (1). The high rate of recurrence and heterogeneity are the 2 major features of HCC (2). The cancer stem cell model (CSC model) proposes that only a rare subset of cancer cells within tumor bulk display the capacity to self-renew, differentiate, and generate a new tumor (3). These CSCs are responsible for sustaining tumor growth and are resistant to conventional treatments (4), accounting for a hierarchical organization of heterogeneous cancer cells and a high rate of cancerous recurrence. Recently, several surface markers, including CD13, CD133, CD24, EpCAM, CD44, and CD90, can be used to enrich liver CSCs (5, 6). However, the hepatic CSC biology remains largely unknown.

Liver CSCs, like other CSCs, behave as stem cells in that they can self-renew and differentiate into heterogeneous tumor cells. Master transcription factor–mediated (TF-mediated) transcriptional regulation is one of the key regulatory mechanisms to determine cell-fate changes (7, 8). OCT4, NANOG, and SOX2 have been defined as the core pluripotent TFs in embryonic stem cells (ESCs). Four TFs (OCT4, SOX2, KLF4, and c-MYC) have been defined as being able to convert differentiated fibroblasts into induced pluripotent stem cells (iPSCs) (9, 10). These findings indicate that core TFs play a central role in establishing and maintaining the pluripotency of stem cells. OCT4, a member of the POU family, exerts a fundamental role in the maintenance of naive pluripotency as a master TF in mammalian development. OCT4 deficiency results in preimplantation lethality of mouse embryos (11). OCT4 is also sufficient to initiate reprogramming of mouse and human somatic cells without other reprogramming factors (12, 13), suggesting that OCT4 plays a crucial role in somatic cell reprogramming. Recent studies have reported that OCT4 is highly expressed in urothelial cancer and ovarian cancer tissues (14, 15). These observations suggest that OCT4 may play an important role in tumorigenesis.

The zinc finger TF ZIC2 belongs to a gene family originally identified by their homology to the drosophila odd-paired genes (16). In both mice and humans, heterozygous deletions or other mutations of ZIC2 cause severe brain malformation, indicating its critical role in the development of the CNS (17). ZIC2 has been reported to be highly expressed in some tumors and implicated in tumorigenesis (18, 19). However, how ZIC2 regulates liver cancer and liver CSCs remains elusive.

Chromatin remodeling is a prerequisite for gene transcription (20), which relies on ATP-dependent chromatin-remodeling complexes. The nuclear remodeling factor complex (NURF complex), a major member of the ISWI subfamily, specifically targets the chromatin via association with sequence-specific TFs and modified histones (21, 22). The NURF complex contains 3 components in mammalian cells, including BPTF, SNF2L, and RBBP4 (also known as RBAP46/48) (23). The NURF complex plays a critical role in the regulation of embryonic development, differentiation, and stemness maintenance (24, 25). The NURF complex can also modulate the canonical WNT pathway, probably through regulating the chromatin structures of targeting genes to make TFs more accessible (26). Recently, we demonstrated that the NURF complex participates in the regulation of self-renewal of hematopoietic stem cells (HSCs) in a c-MYC–dependent manner (27). In this study, we show that ZIC2 is highly expressed in liver CSCs and is required for the
self-renewal of liver CSCs. ZIC2 recruits the NURF complex to trigger OCT4 activation, which sustains the stemness of liver CSCs.

Results

**ZIC2 is highly expressed in liver CSCs.** CD13 and CD133 are widely used as liver CSC markers (6, 28). The CD13^+CD133^+ cell subset exhibited slow growth ability compared with their counterpart CD13^+CD133^+ cells. We previously demonstrated that the CD13^+CD133^+ cell subset was successfully enriched in HCC cell lines and HCC primary samples (29). We isolated CD13^+CD133^+ cell populations from Huh7 and Hep3B cells, since liver CSCs and their sphere-forming abilities were much stronger than those of CD13^+CD133^+ cell subsets (Supplemental Figure 1, A and B; supplemental material available online with this article; doi:10.1172/JCI81979DS1). We previously performed transcriptome microarray analysis of CD13^+CD133^+ cells (hereafter called liver CSCs) and CD13^+CD133^+ cells (hereafter called non-CSCs) sorted from HCC cell lines (GSE66529) (29). We analyzed differential noncoding RNA transcripts in liver CSCs compared with non-CSCs and showed that IncTCF7 is highly expressed in liver CSCs, playing a critical role in the maintenance of liver CSC self-renewal (29).

Here, we wanted to identify which TFs were involved in the maintenance of liver CSC self-renewal. We analyzed TFs based on gene expression profiles of liver CSCs and non-CSCs derived from Huh7 and Hep3B cells. We chose top-10 TFs that were highly expressed in liver CSCs compared with non-CSCs (Figure 1A). We then knocked down these selected TFs and performed in vitro sphere-formation assays. Among these 10 TFs, ZIC2 depletion displayed the strongest inhibitory effect on oncosphere formation (Figure 1B). We next detected ZIC2 expression in HCC patient samples and noticed that ZIC2 was highly expressed in HCC samples, including early and advanced stages (Figure 1C). In parallel, major pluripotency factors, including OCT4, NANOG, SOX2, c-MYC, and KLF4, were also elevated in HCC samples. These observations were validated by immunoblotting (Figure 1D). Moreover, elevated ZIC2 expression was further confirmed by IHC staining (Figure 1E). High expression of ZIC2 in HCC tumors was also confirmed by Wurmbach’s cohort (GSE6764) (ref. 30 and Supplemental Figure 1C). Additionally, we also noticed that ZIC2 was highly expressed in nondifferentiated HCC cell lines versus in differentiated HCC cell lines (GSE36133) (ref. 31 and Supplemental Figure 1D). Finally, high expression of ZIC2 was in agreement with poor prognosis of HCC patients (GSE10186) (ref. 32 and Supplemental Figure 1E). Altogether, ZIC2 is highly expressed in HCC tumor tissues.

We next tested expression levels of ZIC2 in liver CSCs enriched from both HCC cell lines and patient samples. We found that ZIC2 was highly expressed in liver CSCs compared with non-CSCs derived from HCC samples (Figure 2A and Supplemental Figure 2A). In addition, we performed sphere-formation experiments using HCC cell lines and HCC primary sample cells, and detected expression levels of ZIC2. We found that ZIC2 expression was dramatically increased in the oncosphere cells generated by both patient samples and HCC cell lines (Figure 2, B and C, and Supplemental Figure 2B). Moreover, ZIC2 expression was positively correlated with CD13 expression (Figure 2D). Finally, ZIC2 was localized as puncta staining in the nucleus of tumor cells, and similar staining pattern appeared in oncosphere cells (Figure 2E). Taken together, ZIC2 is highly expressed in the nucleus of HCC tumor tissues and liver CSCs.

**ZIC2 is required for self-renewal of liver CSCs.** To further determine the pathological role of ZIC2 in liver CSCs, we knocked out ZIC2 in 8 HCC cell lines using a CRISPR/Cas9 system (Figure 3A). Two ZIC2 KO cell strains were established for each cell line. ZIC2 deletion dramatically declined sphere formation in Huh7, Hep3B, and PLC cells, which had sphere-formation capacity (Figure 3B and Supplemental Figure 3A). Additionally, ZIC2-deficient Hep3B cells remarkably decreased xenograft tumor growth (Figure 3C). We then performed sphere formation and digested oncospheres formed by ZIC2-deficient or control cells into single-cell suspension, then s.c. implanted 1 × 10^4, 1 × 10^3, 1 × 10^2, and 10 cells into BALB/c nude mice. Tumor-initiating capacity was evaluated after 3 months of tumor implantation. ZIC2 deficiency dramatically reduced tumor-initiating capacity (Figure 3D) and declined CSC ratios by a limiting dilution xenograft analysis (Supplemental Table 1A). Similar observations were achieved in other cell lines with ZIC2 deletion. We also silenced ZIC2 in 6 HCC primary cells using a lentivirus-infection system and established ZIC2 knockdown cells (Figure 3E). Two pairs of shRNA sequences obtained similar knockdown efficiency for each sample cell. ZIC2 knockdown significantly decreased sphere formation and xenograft tumor growth (Figure 3F and Supplemental Figure 3, B and C). Similar observations were achieved in all the 6 HCC samples.

We next overexpressed ZIC2 in HCC primary cells and cell lines using lentivirus infection (Supplemental Figure 3D and data not shown). We observed that ZIC2 overexpression in HCC primary cells remarkably increased sphere formation and xenograft growth (Supplemental Figure 3, E and F). We tested 6 HCC samples with similar results. Similar results were obtained by ZIC2 overexpression in cell lines such as Hep3B, Huh7, and PLC cells (Supplemental Figure 3G and data not shown). Altogether, ZIC2 is required for the maintenance of liver CSC self-renewal and tumor propagation.

**ZIC2 initiates activation of OCT4 signaling.** To further determine the underlying mechanism of ZIC2 in the regulation of liver CSCs, we analyzed key TFs related to stemness in ZIC2 KO Hep3B cells. We noticed that OCT4 mRNA was almost undetectable in ZIC2-deficient cells (Figure 4A). Moreover, OCT4 protein levels were remarkably reduced in ZIC2-deficient cells using Western blot (Figure 4B). In addition, ZIC2 deficiency dramatically declined the downstream target genes of OCT4 (Figure 4C). Similar results were obtained in ZIC2-silenced HCC primary cells (Figure 4D).

ZIC2 overexpression in HCC primary cells and cell lines remarkably increased OCT4 expression (Figure 4E and data not shown). Additionally, ZIC2 expression levels were positively correlated with the OCT4 expression levels in HCC tumor tissues (Figure 4F). Expression levels of OCT4 and its target genes were dramatically elevated in liver cancer cells and liver CSCs formed by HCC primary cells and Hep3B cells (Figure 1C, Figure 5A, and Supplemental Figure 4, A–C). Finally, OCT4 expression levels were consistent with the CD13 expression levels (Supplemental Figure 4D). These data suggest that OCT4 is activated in liver CSCs, which was in agreement with the transcriptome microarray data (Figure 1A).

To further confirm the role of OCT4 in the maintenance of liver CSC self-renewal, we knocked down OCT4 in HCC primary cells by 2 pairs of OCT4 shRNAs (Figure 5B). OCT4 knockdown dramatically reduced the capacity of sphere formation (Figure 5C).
and it attenuated xenograft tumor initiating capacity and liver CSC ratios (Figure 5D and Supplemental Table 1B). We silenced OCT4 in 6 HCC primary sample cells with similar observations. In parallel, similar observations were achieved in Hep3B cells (Supplemental Figure 4E). Taken together, OCT4 signaling is essential for the maintenance of liver CSC stemness.

We next overexpressed ZIC2 in OCT4-silenced HCC primary cells. We found that ZIC2 overexpression in OCT4-silenced HCC cells did not promote sphere formation or xenograft tumor growth (Supplemental Figure 5, A and B). Furthermore, we knocked down ZIC2 in OCT4-silenced HCC cells and observed that depletion of ZIC2 in OCT4-silenced HCC cells did not affect either sphere formation or xenograft tumor growth (data not shown). Additionally, ZIC2 knockdown in OCT4-overexpressing HCC cells did not impair OCT4-mediated elevated sphere formation or xenograft tumor growth (Supplemental Figure 5, C and D). Moreover, we rescued WT OCT4 or a dominant-negative mutant OCT4 (33) expression in ZIC2-depleted primary cells (Figure 5E). We noticed...
that WT OCT4 was able to rescue the self-renewal of ZIC2-silenced cells (Figure 5F), whereas the dominant-negative mutant OCT4 had no such activity. We tested 6 HCC samples with similar results (Supplemental Figure 5E). We concluded that ZIC2 drives self-renewal of liver CSCs upstream of OCT4.

ZIC2 binds to the OCT4 promoter for its activation. We next performed a ChIP assay in primary oncospheres using anti-ZIC2 antibody. We analyzed a 3-kb locus upstream from the transcription start site (TSS) of the OCT4 gene promoter. We observed that a −2,530−2,447 bp region of the OCT4 promoter upstream from the TSS was occupied by ZIC2 protein (Figure 6A). We tested 3 HCC primary specimens with similar results. Similar results were achieved in Hep3B cells (Supplemental Figure 6A). To confirm that OCT4 was activated by ZIC2, we performed luciferase reporter assays. We identified a −2,550−2,430 bp fragment of the OCT4 promoter (CR4 region) bound to the ZIC2 protein (Supplemental Figure 6, B and C). Finally, the ZIC2 binding of the OCT4 promoter was confirmed by a gel EMSA (Figure 6B).

We next wanted to determine the physiological function of the ZIC2 binding to the OCT4 promoter. We examined chromatin accessibility of the OCT4 locus by a standard DNase I digestion assay. We found that ZIC2 KO remarkably attenuated chromatin accessibility of the OCT4 locus (Figure 6C). Moreover, ZIC2 deficiency significantly reduced the H3K4 tri-methylation (H3K4Me3) level on the OCT4 locus (Figure 6D), a major hallmark of transcription activation. Six HCC primary samples showed similar observations (Figure 6E). By contrast, ZIC2 overexpression dramatically enhanced both the chromatin accessibility of the OCT4 locus and the H3K4Me3 level of the

Figure 2. ZIC2 is elevated in liver CSCs. (A) ZIC2 is highly expressed in CD13+CD133+ primary cells. (B and C) ZIC2 is more highly expressed in oncospheres derived from HCC sample cells than nonsphere tumor cells by quantitative RT-PCR (B) and immunoblotting (C). (D) ZIC2 and CD13 expression was detected by quantitative RT-PCR, followed by correlation analysis. (E) HCC primary cells and spheres were permeabilized and stained with anti-ZIC2 and anti-CD13 antibodies, then counterstained with DAPI followed by confocal microscopy. Scale bars: 20 μm. Data are shown as means ± SD. Two-tailed Student’s t test was used for statistical analysis. *P < 0.05; **P < 0.01; and ***P < 0.001. Data are representative of at least 3 independent experiments.
ZIC2 interacts with the NURF complex. To further elucidate the molecular mechanism of ZIC2 in regulating OCT4 expression, we screened interacting candidates using ZIC2 as bait with a yeast 2 hybrid system. We deleted the DNA-binding domain of ZIC2 (aa 255-415) to subclone into pGBKT7 plasmid (BD-ZIC2Δ). We identified that RBBP4 gene was an interactor for ZIC2 and further confirmed by yeast 2 hybrid assays (Figure 7A). RBBP4 is a component of the NURF complex. Their direct interaction was verified by a pulldown assay (Supplemental Figure 7A). With a coimmunoprecipitation (Co-IP) assay, anti-ZIC2 antibody could precipitate RBBP4 in primary sphere cell lysates, as well as the other 2 components BPTF and SNF2L (Figure 7B). In addition, we next performed ChIP immunoblots with elution gradients. With crosslinking treatment, ZIC2 coeluted with the components of the OCT4 locus (Supplemental Figure 6, D–F). These results suggest that ZIC2 binds to the promoter of OCT4 that initiates its activation.

We next explored whether ZIC2 sustains the self-renewal of liver CSCs via binding to OCT4 promoter. We deleted the ZIC2 binding sequence of OCT4 promoter in Hep3B cells using a CRISPER/Cas9 lentivirus system, which was confirmed by DNA sequencing (Supplemental Figure 6G). We found that ZIC2 overexpression did not enhance OCT4 expression in the OCT4 promoter binding sequence–deleted Hep3B cells (Supplemental Figure 6H). Consequently, these cells failed to promote sphere formation (Figure 6F and Supplemental Figure 6I) and xenograft tumor propagation (Supplemental Figure 6J). These data indicate that ZIC2 binding to the OCT4 promoter is necessary for ZIC2-initiated self-renewal of liver CSCs.
NURF complex (Figure 7C). In parallel, BPTF was also associated with ZIC2 in a chromatin-binding fashion (Figure 7D). These data indicate that the interaction of ZIC2 with the NURF complex is chromatin embedded.

Colocalization of ZIC2 with the NURF complex in the nucleus was visualized in HCC primary cells and their oncosphere cells by confocal microscopy (Figure 7E). Similar observations were obtained in Hep3B cells and their oncospheres (Supplemental Figure 7B). IHC staining showed merged staining of ZIC2 with the NURF complex (Figure 7F and data not shown).

We next tested expression levels of the NURF complex in liver CSCs. We noticed that the components of the NURF complex were highly expressed in liver CSCs derived from HCC samples and oncosphere cells generated from HCC samples (Supplemental Figure 8, A and B). Additionally, the expression levels of the 3 components of the NURF complex were positively correlated with the CD13 expression level in HCC samples (Supplemental Figure 8C). Finally, the expression levels of the 3 components of the NURF complex were significantly elevated in CD13hi samples compared with CD13lo samples provided by the Wang’s cohort dataset (GSE14520) (ref. 34 and Supplemental Figure 8D). Overall, these data indicate that ZIC2 interacts with the NURF complex in the nucleus of HCC cells.

The NURF complex is required for self-renewal of liver CSCs. To explore the role of the NURF complex in the regulation of liver CSCs, we silenced each component of the NURF complex in HCC primary cells (Figure 8A, left panel). Knockdown of the NURF components remarkably suppressed OCT4 expression in HCC primary cells (Figure 8A, right panel). Similar results were obtained using Hep3B cells (Supplemental Figure 9A). Furthermore, knockdown of the NURF complex significantly reduced chromatin accessibility of the OCT4 locus (Supplemental Figure 9B). The NURF complex bound to the OCT4 promoter by ChIP assays (Supplemental Figure 9C). Coincidently, the NURF complex occupied the CR4 region of the OCT4 promoter, the same region as ZIC2. Importantly, the CR4 region of the OCT4 promoter displayed much lower levels of H3K4Me3 in NURF complex–silenced primary cells (Supplemental Figure 9D). These data suggest that the NURF complex enhances OCT4 expression.

Of note, knockdown of the NURF components in HCC primary cells and cell lines dramatically reduced sphere formation and xenograft growth (Figure 8B and Supplemental Figure 9, E and F). Additionally, depletion of the NURF components in HCC primary cells markedly reduced tumor initiating capacity (Figure 8C) and CSC ratios by a limiting-dilution xenograft analysis (Supplemental Table 1C). We tested 6 HCC samples and achieved similar results. To further verify the relatively physiological role of the NURF complex, we knocked out BPTF, a core component of the
The NURF complex, in HCC cell lines using a CRISPR/Cas9 system (Figure 8D). We found that BPTF deficiency remarkably impaired OCT4 expression and sphere formation (Figure 8, D and E, and Supplemental Figure 9G), which was in agreement with the NURF complex–silencing results.

We next rescued WT or mutant OCT4 expression in NURF-depleted HCC primary cells (Supplemental Figure 10A). We found that WT OCT4 could predominantly restore the self-renewal of NURF-depleted cells, whereas mutant OCT4 had no such effect (Supplemental Figure 10, B and C), suggesting that the NURF complex promotes liver CSC self-renewal via OCT4 signaling. Importantly, depletion of ZIC2 abolished its binding capacity to the NURF complex, leading to disassociation from the OCT4 promoter (Figure 8F). However, depletion of the NURF complex did not affect the binding capacity of ZIC2 to the OCT4 promoter (Supplemental Figure 10D), suggesting that the NURF complex directly regulated OCT4 expression. In sum, NURF complex-mediated OCT4 activation is required for the self-renewal maintenance of liver CSCs.

**NURF complex levels are consistent with HCC severity and prognosis.** As shown above, the NURF complex was highly expressed in liver CSCs and involved in the regulation of liver CSCs. We further wanted to explore whether the NURF complex was implicated in HCC progression. Firstly, we analyzed NURF expression levels using Wang’s cohort (GSE14520). The 3 NURF complex components were significantly highly expressed in HCC tumor tissues (Figure 9A). We tested the NURF complex expression in HCC samples through quantitative RT-PCR and immunoblotting. The NURF complex was highly expressed in HCC patients (Figure 9, B and C). Additionally, the expression levels of the NURF complex were well correlated with clinicopathological stages of HCC patients (Figure 9B). This result was further validated by IHC staining (Figure 9D).

**Figure 5. OCT4 activation is required for the maintenance of liver CSCs.** (A) OCT4 is highly expressed in spheres generated by HCC primary cells. (B and C) OCT4 was knocked down in HCC primary cells (B) and OCT4-silenced primary cells were cultured for sphere-formation assays (C). (D) The indicated cells were digested into single cells and then injected into BALB/c nude mice with different dilutions. (E and F) ZIC2-depleted primary cells were established and rescued with functional OCT4 and dominant-negative mutant OCT4 (E), then self-renewal was measured in sphere-formation medium (F). Z2, ZIC2; O4, OCT4; Vec, vector; Mut, mutation. Scale bars: 500 μm (C and F). Data are shown as means ± SD. Two-tailed Student’s t test was used for statistical analysis. **P < 0.01 and ***P < 0.001. Data are representative of at least 3 independent experiments.
CSCs may be responsible for cancer relapse and metastasis due to their invasive and drug-resistant capacities (38). Several surface markers have been identified to enrich liver CSCs, whose heterogeneous markers may represent different cellular origins (39). However, it remains largely unknown about hepatic CSC biology. In this study, we analyzed differential TFs from our transcriptome microarray datasets derived from liver CSCs (29). We found the TF ZIC2 is highly expressed in liver CSCs. ZIC2 is required for the self-renewal maintenance of liver CSCs upstream of OCT4 activation signaling. ZIC2 recruits the NURF complex to the OCT4 promoter that initiates OCT4 activation. Expression levels of the NURF complex are consistent with clinical severity and prognosis of HCC patients.

Expression levels of the NURF complex in tumor tissues are consistent with clinical severity and prognosis of HCC patients.

Discussion

Twenty years ago, Dick and colleagues firstly isolated the CD34+/CD38– leukemic subpopulation cells as leukemic CSCs (36). Subsequently, CSCs have been identified in many other solid tumors, including breast, lung, brain, liver, colon, prostate, and bladder cancers (3, 6, 37). CSCs harbor similar characteristics associated with normal tissue stem cells, including self-renewal, differentiation, and the ability to form a new tumor. CSCs may be responsible for cancer relapse and metastasis due to their invasive and drug-resistant capacities (38). Several surface markers have been identified to enrich liver CSCs, whose heterogeneous markers may represent different cellular origins (39). However, it remains largely unknown about hepatic CSC biology. In this study, we analyzed differential TFs from our transcriptome microarray datasets derived from liver CSCs (29). We found the TF ZIC2 is highly expressed in liver CSCs. ZIC2 is required for the self-renewal maintenance of liver CSCs upstream of OCT4 activation signaling. ZIC2 recruits the NURF complex to the OCT4 promoter that initiates OCT4 activation. Expression levels of the NURF complex are consistent with clinical severity and prognosis of HCC patients.

Elucidation of signaling pathways that modulate the maintenance and survival of liver CSCs is important for the understanding of hepatic CSC biology and the development of novel therapies against HCC. Several signaling pathways, such as WNT, TGF-β, AKT, and STAT3 pathways, have been defined to be implicated in maintaining CSCs.
in the regulation of liver CSCs (39). Not surprisingly, some liver CSC subsets and normal tissue stem cells may share core regulatory genes and common signaling pathways. In this study, we found that OCT4 is highly expressed in liver CSCs and is essential for the maintenance of liver CSCs. The TF OCT4, encoded by the Pou5f1 gene, is a member of the POU family. OCT4 is required for the stemness properties of ESCs (11), suggesting it is an essential factor in early development of mammalian embryogenesis. Importantly, OCT4 harbors oncogenic potential (40, 41). Moreover, it has been reported that OCT4 is involved in the maintenance of lung

Figure 7. ZIC2 interacts with the NURF complex. (A) ZIC2 associates with RBBP4. Yeast strain AH109 was cotransfected with Gal4 DNA-binding domain (BD) fused the DNA binding region–deleted (aa 255–415) ZIC2 gene (BD-ZIC2ΔDB), and Gal4-AD–fused RBBP4. Selected clones were detected for β-galactosidase activity. p53 and large T antigen were used as a positive control. (B) Anti-ZIC2 antibody precipitated the NURF complex from primary sphere lysates by Co-IP assay. (C and D) HCC sample sphere cells were treated with 1% formaldehyde for crosslinking. Then anti-ZIC2 (C) or anti-BPTF antibody (D) was incubated with treated lysates for ChIP assays, followed by size fractionation with sucrose gradient ultracentrifugation. Eluate gradients were used for Western blot and PCR assays. (E) ZIC2 colocalizes with BPTF. HCC primary nonsphere cells and spheres were stained for BPTF and ZIC2, counterstained with DAPI. SNF2L and RBBP4 were also merged with ZIC2 (data not shown). Scale bar: 10 μm. (F) ZIC2 and BPTF were costained by IHC staining. Blue arrowhead denotes ZIC2, red arrowhead indicates BPTF, and black arrowhead indicates merge of ZIC2 and BPTF. Scale bars: 50 μm. Data are representative of at least 3 independent experiments.
CSCs, as well as the regulation of tumor progression in bladder cancer (42, 43). Here, we showed that OCT4 is required for the self-renewal maintenance of liver CSCs, suggesting that OCT4 plays a critical role in the regulation of liver CSCs and tumor propagation.

OCT4 acts as a gatekeeper in the beginning of mammalian development; it regulates the transcription of many genes, such as FOXO15, ZNF42, REX1, FGF4, SOX2, NANOG, and so on. However, how OCT4 expression is regulated remains largely unknown. Here, we observed that ZIC2 can bind to the fourth region (CR4) of OCT4 promoter, which triggers OCT4 expression in liver CSCs. The ZIC TF family members (ZIC1-5) contain highly conserved C2H2-class zinc finger motifs and are involved in early embryonic development. ZIC2 mutations cause human holoprosencephaly (44). A recent report showed that ZIC2 is highly expressed in cervical cancer and associated with activation of Hedgehog signaling (18). Here, we found that ZIC2 is constitutively expressed in liver CSCs and participates in the regulation of liver CSC maintenance. Actually, ZIC2 is also highly expressed in ESCs, iPSCs, and 2/3 partial hepatectomy–regenerated (PH-regenerated) liver cells (data not shown). These data suggest that ZIC2 plays a crucial role in the maintenance and survival of both normal stem cells and CSCs.

Figure 8. The NURF complex is required for self-renewal of liver CSCs. (A) The NURF complex enhances OCT4 expression. The NURF components were knocked down followed by detection of OCT4 expression. (B) Sphere formation was performed with NURF complex silenced primary cells. Six HCC samples obtained similar results. (C) Oncospheres generated by BPTF-, SNF2L-, and RBBP4-silenced primary cells were digested for gradient injection. Percentage of tumor-formation mice was calculated. (D) BPTF-deficient cells were established by a CRISPR/CAS9 system. BPTF deficiency was verified by Western blot. (E) BPTF-KO cells were cultured for sphere-formation assays. Similar results were achieved in the tested 3 cell lines. (F) ChIP assays were performed using the indicated anti-NURF antibodies, and then OCT4 promoter enrichment regions were examined by quantitative RT-PCR. Scale bars: 500 μm (B and E). Data are shown as means ± SD. Two-tailed Student’s t test was used for statistical analysis. *P < 0.05 and **P < 0.01. Data are representative of at least 3 independent experiments.
Wnt signaling pathway via modulating the chromatin structures of targeting genes to make transcriptional regulators more accessible (26). We previously showed that the NURF complex can be recruited on the \textit{c-MYC} promoter for its activation, which regulates the self-renewal of HSCs (27). Here, we showed that ZIC2 can recruit the NURF complex to the \textit{OCT4} promoter for its initiation, which modulates the maintenance and survival of liver CSCs. These findings indicate that the NURF complex is implicated in the tumorigenesis of HCC.

Based on our online-cohort dataset analysis and experimental results, the NURF complex is highly expressed in HCC tumors and liver CSCs. The NURF complex knockdown or deletion impairs mechanisms determining cell fate, which includes cis-regulatory elements and transacting factors. Among all transacting factors, chromatin-remodeling regulation plays a pivotal role in gene transcription (20, 47), which depends on ATP-dependent chromatin remodeling complexes. Based on a common SWI2/SNF2-related catalytic ATPase subunit, the chromatin remodeling complexes are classified into 4 major subfamilies, which are SWI/SNF, ISWI, CHD, and INO80 (48). The NURF complex is a core member of the ISWI subfamily. The NURF complex consists of 4 subunits in \textit{drosophila} (NURF301, NUFF55, NURF38, and ISWI) and 3 components in mammalian cells (BPTF, RBBP4, and SNF2L) (49). The NURF complex can regulate the canonical Wnt signaling pathway via modulating the chromatin structures of targeting genes to make transcriptional regulators more accessible (26). We previously showed that the NURF complex can be recruited on the \textit{c-MYC} promoter for its activation, which regulates the self-renewal of HSCs (27). Here, we showed that ZIC2 can recruit the NURF complex to the \textit{OCT4} promoter for its initiation, which modulates the maintenance and survival of liver CSCs. These findings indicate that the NURF complex is implicated in the tumorigenesis of HCC.

Based on our online-cohort dataset analysis and experimental results, the NURF complex is highly expressed in HCC tumors and liver CSCs. The NURF complex knockdown or deletion impairs mechanisms determining cell fate, which includes cis-regulatory elements and transacting factors. Among all transacting factors, chromatin-remodeling regulation plays a pivotal role in gene transcription (20, 47), which depends on ATP-dependent chromatin remodeling complexes. Based on a common SWI2/SNF2-related catalytic ATPase subunit, the chromatin remodeling complexes are classified into 4 major subfamilies, which are SWI/SNF, ISWI, CHD, and INO80 (48). The NURF complex is a core member of the ISWI subfamily. The NURF complex consists of 4 subunits in \textit{drosophila} (NURF301, NUFF55, NURF38, and ISWI) and 3 components in mammalian cells (BPTF, RBBP4, and SNF2L) (49). The NURF complex can regulate the canonical Wnt signaling pathway via modulating the chromatin structures of targeting genes to make transcriptional regulators more accessible (26). We previously showed that the NURF complex can be recruited on the \textit{c-MYC} promoter for its activation, which regulates the self-renewal of HSCs (27). Here, we showed that ZIC2 can recruit the NURF complex to the \textit{OCT4} promoter for its initiation, which modulates the maintenance and survival of liver CSCs. These findings indicate that the NURF complex is implicated in the tumorigenesis of HCC.

Based on our online-cohort dataset analysis and experimental results, the NURF complex is highly expressed in HCC tumors and liver CSCs. The NURF complex knockdown or deletion impairs mechanisms determining cell fate, which includes cis-regulatory elements and transacting factors. Among all transacting factors, chromatin-remodeling regulation plays a pivotal role in gene transcription (20, 47), which depends on ATP-dependent chromatin remodeling complexes. Based on a common SWI2/SNF2-related catalytic ATPase subunit, the chromatin remodeling complexes are classified into 4 major subfamilies, which are SWI/SNF, ISWI, CHD, and INO80 (48). The NURF complex is a core member of the ISWI subfamily. The NURF complex consists of 4 subunits in \textit{drosophila} (NURF301, NUFF55, NURF38, and ISWI) and 3 components in mammalian cells (BPTF, RBBP4, and SNF2L) (49). The NURF complex can regulate the canonical Wnt signaling pathway via modulating the chromatin structures of targeting genes to make transcriptional regulators more accessible (26). We previously showed that the NURF complex can be recruited on the \textit{c-MYC} promoter for its activation, which regulates the self-renewal of HSCs (27). Here, we showed that ZIC2 can recruit the NURF complex to the \textit{OCT4} promoter for its initiation, which modulates the maintenance and survival of liver CSCs. These findings indicate that the NURF complex is implicated in the tumorigenesis of HCC.

Based on our online-cohort dataset analysis and experimental results, the NURF complex is highly expressed in HCC tumors and liver CSCs. The NURF complex knockdown or deletion impairs mechanisms determining cell fate, which includes cis-regulatory elements and transacting factors. Among all transacting factors, chromatin-remodeling regulation plays a pivotal role in gene transcription (20, 47), which depends on ATP-dependent chromatin remodeling complexes. Based on a common SWI2/SNF2-related catalytic ATPase subunit, the chromatin remodeling complexes are classified into 4 major subfamilies, which are SWI/SNF, ISWI, CHD, and INO80 (48). The NURF complex is a core member of the ISWI subfamily. The NURF complex consists of 4 subunits in \textit{drosophila} (NURF301, NUFF55, NURF38, and ISWI) and 3 components in mammalian cells (BPTF, RBBP4, and SNF2L) (49). The NURF complex can regulate the canonical Wnt signaling pathway via modulating the chromatin structures of targeting genes to make transcriptional regulators more accessible (26). We previously showed that the NURF complex can be recruited on the \textit{c-MYC} promoter for its activation, which regulates the self-renewal of HSCs (27). Here, we showed that ZIC2 can recruit the NURF complex to the \textit{OCT4} promoter for its initiation, which modulates the maintenance and survival of liver CSCs. These findings indicate that the NURF complex is implicated in the tumorigenesis of HCC.

Based on our online-cohort dataset analysis and experimental results, the NURF complex is highly expressed in HCC tumors and liver CSCs. The NURF complex knockdown or deletion impairs mechanisms determining cell fate, which includes cis-regulatory elements and transacting factors.
the self-renewal maintenance of liver CSCs and tumor initiation. Importantly, the expression levels of the NURF complex are positively correlated with clinical severity and prognosis of HCC patients. Moreover, ZIC2 and OCT4 are also required for the maintenance and survival of liver CSCs, which are positively related to the clinicopathological stages of HCC patients. In summary, ZIC2, OCT4, and the NURF complex can be detected for the diagnosis and prognosis prediction of HCC patients, which might be used as targets for eradicating liver CSCs for future therapy.

Methods

Gene expression analyses. Cohort datasets were downloaded from NCBI or EBI. R language and Bioconductor was used for background correction, normalization, calculation of gene expression, and annotation (50). Genes and expression lists generated by R3.1.0 were used for further analysis.

HCC cell lines. Human HCC cell line Hep3B, PLC, LM3, 7721, HepG2, and HuH7 were provided by Zeguang Han (Shanghai Jiaotong University School of Medicine, Shanghai, China); 7704 and 7402 were provided by Pengyuan Yang (Institute of Biophysics, Chinese Academy of Sciences, Beijing, China). HCC cells were grown in DMEM medium supplemented with 10% FBS (Invitrogen), 100 μg/ml penicillin, and 100 U/ml streptomycin.

Antibodies and regents. Anti-β-actin (catalog A1978), anti-Flag (catalog F1804) Abs were purchased from Sigma-Aldrich. Anti-ZIC2 (catalog ARP35821_P050) antibody was obtained from Aviva Systems Biology. Anti-OCT4 (catalog 2750) antibody was purchased from Cell Signaling Technology. Anti-SNF2L (catalog 61465) antibody was purchased from Active Motif. Anti-BPTF (catalog bs-11641R) antibody was obtained from Bioss Inc. Anti-RBBP4 (catalog 20364-1-AP) antibody was purchased from Proteintech Group, Inc. FITC-conjugated CD13 antibody (catalog 11-0138) was obtained from ebioscience. Phycoerythrin-conjugated (PE-conjugated) CD133 (catalog 130098836) was purchased from Miltenyi Biotec. Alexa488-conjugated donkey anti-mouse IgG (catalog R37114), Alexa594-conjugated donkey anti-mouse IgG (catalog R37115), and Alexa594-conjugated donkey anti-rabbit IgG (catalog R37119) Abs were obtained from Invitrogen. Alkaline phosphatase-conjugated (AP-conjugated) secondary antibody (catalog BA1011) was obtained from Wuhan Bolster Biological Technology, Ltd. HRP-conjugated secondary antibody (catalog sc-2004, sc-2005) was obtained from Santa Cruz Biotechnology, Inc. bFGF (catalog GF446-50UG) was obtained from Millipore. EGF (catalog E5036-200UG), PEG5000 (catalog 175233-46-2), and DAPI (catalog 28718-90-3) were purchased from Sigma-Aldrich. N2 supplement (catalog 17502-048) and B27 (catalog 17504-044) were obtained from Invitrogen. Dual-detection luciferase detection kit (catalog E1910) was purchased from Promega.

Quantitative RT-PCR. mRNA was extracted according to standard protocols provided by Invitrogen. The total mRNA served as a template, and reverse transcription PCR was followed by standard protocols from Promega Company. cDNA was examined for gene expression by quantitative RT-PCR. For ChIP assay, extracted DNA fragments and input genomic DNA served as a template. The primer sequences we used are shown in the Supplemental Table 2.

Western blot. Western blot was performed as described (27). For details, specimens or spheres derived from primary cells were homogenized with RIPA buffer (150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP40, 1 mM EDTA, and 50 mM Tris [pH 8.0]) supplemented with cocktail protease inhibitor (Roche Diagnostics). After boiling for 15 minutes, supernatants were loaded for SDS-PAGE. Nitrocellulose membranes were incubated with primary antibodies for immunoblotting, then incubated and visualized by HRP-conjugated secondary antibodies.

CRISPR/Cas9 KO system. ZIC2- and BPTF-deficient Hep3B cells were established using a CRISPR/Cas9 system according to the standard protocol provided by Zhang’s lab (51). Briefly, single guide RNA (sgRNA) was generated by online CRISPR Design Tool (http://tools.genome-engineering.org) and cloned into pSPCas9 (BB)-2A-GFP vector. After confirming the cutting efficiency of sgRNA, pSPCas9 vectors were transfected into Hep3B cells. Sorted GFP+ Hep3B cells were seeded into 96-well plates for monoclonalization. Four weeks later, the cell clones derived from single cells were detected for gene expression. The sgRNA sequences of ZIC2 were 5′-CCATCACACATCGCCGCGG-3′ and 5′-TTCAAGGTGCTGACATCTCGG-3′. The sgRNA sequences of BPTF were 5′-CCCCCCCCATGGGTGGTCGGGAGC-3′ and 5′-CCCCGCCCTCGGACTGATG-3′.

For deletion of the ZIC2 binding sequence of OCT4 promoter in Hep3B cells, we used LenttiCRISPRv2 (catalog 52961), pSV5G (catalog 8454), and pSPAX2 (catalog 12260) plasmids purchased from AddGene. We produced lentivirus in 293T cells and infected Hep3B cells with lentivirus, followed by puromycin selection and monoclonalization. sgRNA sequences of the OCT4 promoter were: OCT4 promoter KO #1: 5′-GTCGCGGTATGTTGTCGCC-3′ (F) and 5′-GGAGGAGAACATGCCTTGCGAAC-3′ (R); OCT4 promoter KO #2: 5′-CCTCTGAGGCCGTCCTCTC-3′ (F) and 5′-TGGCCCTTTAACTGCCCCAAA-3′ (R). Selected cell clones with deletion of the ZIC2 binding sequence of OCT4 promoter were confirmed by DNA sequencing.

IHC assay. Formalin-fixed tumor tissue sections were deparaffinized in xylene (10 minutes, twice), rehydrated in graded alcohols (100%, 100%, 95%, 85%, and 70% alcohols), and finally submerged in distilled water. After treated in 3% Hydrogen Peroxide (H2O2) for 15 minutes, the slides were processed for antigen retrieval in Tris-EDTA buffer (10 mM, pH 8.0), 121°C for 5 minutes, and then cooled down slowly. After blocking with 10% goat serum for 30 minutes, the sections were incubated in primary antibodies overnight. After washing 3 times with PBS, the sections were incubated in HRP or AP-conjugated secondary antibodies, and subsequent detection was performed using the standard substrate detection of HRP or AP. Then, the sections were stained with hematoxylin and dehydration in graded alcohols and xylene. For double staining, there was no counterstaining with hematoxylin.

Co-IP assay. For Co-IP, sphere cells (5 × 10⁶) were harvested, washed 3 times with PBS, and then treated with RIPA buffer for 30 minutes at 4°C. Precipitation was removed from cell lysate by centrifugation, and the supernatants were precleared for 1 hour by protein A/G beads (Santa Cruz Biotechnology Inc.). Then, the precleared protein A/G beads were removed and primary antibodies were added for incubation overnight. New protein A/G beads were added for IP. Finally the precipitate was collected and detected as described (27).

Lentivirus production and cell infection. ZIC2 plasmid was provided by Eloisa Herrera (Instituto de Neurociencias de Alicante, Campus San Juan, Avd. Ramón y Cajal s/n, Alicante 03550, Spain). We constructed Pbbplv-GFP-Flag-ZIC2 using ZIC2 plasmid as a template. For virus production, we transfected 293T cells with Pbbplv-GFP or Pbbplv-GFP-Flag-ZIC2 plasmid, along with packaging plasmids. Hep3B and HCC primary cells were infected by the virus supernatants. After sorting for GFP+ cells, we established ZIC2 overexpression cells.
ZIC2-, OCT4-, and NURF complex–silenced Hep3B or HCC primary cells were established using pShicoR-GFP shRNA vectors by a similar strategy. shRNA sequences are listed in Supplemental Table 3.

**Sphere formation assay.** Hep3B cells (1,000) or HCC primary cells (5,000) were seeded in Ultra Low Attachment 6-well plates (Corning Inc.) and cultured in Dulbecco’s modified Eagle’s medium/F12 supplemented with B27, N2 (Invitrogen), 20 ng/ml EGF, and 20 ng/ml Basic Fibroblast Growth Factor (Millipore). Cells were incubated in a CO₂ incubator 2 weeks later; spheres were counted under stereomicroscope (Olympus). We collected medium containing nonsphere cells and spheres into an eppendorf tube and let stand for 5 minutes for sphere/nonsphere separation. The pellets were spheres, and supernatants were nonsphere cells. The spheres were fixed for immunofluorescence staining or digested for Co-IP and Western blot assays. Supernatants were then removed into a new eppendorf tube with transferpettor and collected by centrifugation at 4,000 rpm for 5 minutes. Pellets were nonsphere cells and used directly for subsequent experiments. We cultured these nonsphere cells under the same nonadherent conditions as sphere cells.

**Flow cytometry.** Cells were labeled with FITC-conjugated CD13 and PE-conjugated CD133 antibodies followed by CSC isolation. For FACS analysis, cells were incubated either with fluorescence-conjugated antibodies or with primary antibodies and further fluorescence-conjugated secondary antibodies.

**Yeast 2-hybrid.** Yeast 2-hybrid screening was performed using Matchmaker Gold Yeast 2-Hybrid system (Takara Bio Inc.) followed by the guidelines of the manufacturer’s instruction (52). Briefly, the DNA binding region–deleted (aa 255–415) ZIC2 gene was cloned into pGBKTT7 plasmid (BD-ZIC2ADB). BD-ZIC2ADB and plasmids containing Gal4-activating domain (AD) fused human liver library (Takara Bio Inc.) were cotransformed into the AH109 yeast strain. Then, the transformed yeasts were grown on plates with SD medium lacking adenine, histidine, tryptophan, and leucine. Selected clones were isolated and identified by DNA sequencing. Recovery of the plasmids and β-gal assay were performed as described (52).

**Immunofluorescence staining.** Cells were fixed by 4% paraformaldehyde (PFA) for 20 minutes and penetrated by 0.5% tritonX-100 for 30 minutes. After blocking with 10% FBS, primary antibodies were added and incubated overnight at 4°C. After washing 3 times with PBS, fluorescence-conjugated secondary antibodies were added for observation by confocal microscopy. For HCC tissue samples, specimens were treated with 3% hydrogen peroxide and then Tris-EDTA buffer and lysed by lysis buffer followed by detection of luciferase activity.

**In vivo xenograft experiments.** Six-week-old female BALB/c normal mice and nude mice were obtained from the Animal Center of the Chinese Academy of Medical Sciences (Beijing, China). For tumor-initiating assays, 6 BALB/c nude mice were used every sample. Tumor-initiating cell frequencies were calculated using extreme limiting dilution analysis (54). Tumor cells (1 × 10⁶) were injected into 6-week-old BALB/c nude mice. Every 5 days, tumor volume was calculated as described (55). For tumor-formation assays, spheres were digested into single cells by Trypsin/EDTA, and indicated gradient cells were injected into BALB/c nude mice. Tumor formation was evaluated at the third month. For xenograft tumor propagation, 5 BALB/c nude mice were used for one sample.

**Statistics.** Tumor-initiating cell frequencies were calculated using extreme limiting dilution analysis (54). Statistical significance was evaluated using a 2-tailed Student’s t test. P values less than 0.05 were considered significant.

**Study approval.** Human liver cancer specimens were obtained from the Department of Hepatobiliary Surgery, PLA General Hospital (Beijing, China) with informed consent, according to the Institutional Review Board approval. All experiments involving mice were approved by the institutional committee of Institute of Biophysics, Chinese Academy of Sciences.

**Acknowledgments**

We thank Junying Jia (Institute of Biophysics, CAS) and Jing Li (Cnkingbio Co. Ltd, Beijing, China) for technical support. This work was supported by the National Natural Science Foundation of China (81330047, 91419308, 81272270, 81402459, and 81101531); the State Projects of Essential Drug Research and Development (2012ZX0910301-041); 973 Program of the Ministry of Science and Technology of China (2015CB553705, 2010CB919102); and the Strategic Priority Research Programs of the Chinese Academy of Sciences (XDA01010407).

Address correspondence to: Zusen Fan, The CAS key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China 100101. Phone: 86.10.64888457; E-mail: fanz@moon.ibp.ac.cn.